Tencent-backed biopharmaceutical company Libang Pharma (9637) began its Hong Kong IPO subscription period on Thursday through next Wednesday (24), according to Ming Pao, offering 56.7554 million H shares globally with 10% allocated to Hong Kong and the remainder to international investors.
The offer price is set at HK$22.6 per share, with maximum proceeds of about HK$1.283 billion.
STOCKS | Tencent-Backed Libang Pharma Starts Hong Kong IPO Bookbuilding
2026-06-18 01:10:42
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
